Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Fresenius USA

This article was originally published in The Gray Sheet

Executive Summary

Fresenius USA: Firm's shareholders will receive approximately 1.112 American Depositary Shares (ADS) of the combined National Medical Care and Fresenius AG business -- Fresenius Medical Care AG -- for each share of Fresenius USA under a plan announced May 8. The plan allows Fresenius USA shareholders to "participate" in the pending combination of Grace's NMC with Fresenius AG ("The Gray Sheet" Feb. 12, p. 8). "Each ADS will evidence one-third of an ordinary share of Fresenius Medical Care AG," Fresenius USA and Fresenius AG say, noting that the exchange ratio is based on "the current intent" that 70 mil. ordinary shares of Fresenius Medical Care AG will be outstanding. After the deal's closing, Fresenius AG, Grace, and Fresenius USA shareholders will hold 50.3%, 44.8%, and 4.9% of the combined business, respectively...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT005969

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel